摘要：In the present study,we aimed to investigate the pharmacokinetics and dosage proportionality for a single,intravenous utilization of Pazufloxacin Mesilate Sodium Chloride,an injectable synthetic fluoroquinolone antibacterial agent,in healthy Chinese *** this open-labeled,three-dosage parallel study,subjects were randomized to receive a single dose of Pazufloxacin Mesilate at 150,300 or 600 mg(n=10,10 and 10,respectively)administered as a 30-min intravenous *** and urine samples were serially collected from 0 to 24 h after drug ***,the sample’s drug concentrations were analyzed via validated RP-HPLC *** receiving a single dose of Pazufloxacin Mesilate 150,300 or 600 mg were in accordance with the two compartment *** Cmax for each dosage group was 2.37±0.89,4.27±0.74 and 10.74±4.06 mg·mL(–1),respectively;and the AUC0→∞was 3.24±1.2,5.89±1.51 and 13.32±2.35 mg·h·mL–1,*** addition,Tmax for groups treated with 150,300 and 600 mg was 0.48±0.08,0.50±0.00 and 0.53±0.08 h,*** correlation analysis for AUC0→∞,Cmax and dosage suggested that pazufolxacin mesilate displayed dose proportion at the dose ranging from 150 to 600 *** data suggested that all three different dosage regimens fit with the two compartment ***,it presented a linear correlation between AUC0→∞,Cmax and dosage over the range of 150–600 mg.